Introduction
Foot-and-mouth disease virus (FMDV) exists as seven major serotypes and numerous subtypes and is of great economic importance because of the direct and indirect consequences of infection of cattle, pigs, sheep and goats. Vaccination with inactivated whole virus does not protect across the serotypes, and even between some subtypes, and confers a relatively short duration of immunity. For these and many other reasons, several groups have attempted to develop synthetic or biosynthetic alternatives to conventional vaccines. The greatest progress has been achieved using peptides corresponding to the surface-exposed G-H loop of VP1 of FMDV, which can elicit a neutralizing antibody response (Bittle et aI., 1982; Pfaff et al., 1982) , and are protective in target species (DiMarchi et al., 1986; Doel et al., 1990) . Such effectiveness at mimicking the immunogenicity of the * Author for correspondence. Fax +44 1483 232448. t Present address: Rh6ne M~rieux Limited, Ash Road, Pirbright, Surrey GU24 0NQ, UK.
G-H loop is probably due to the unusually flexible nature of the sequence in the native particle (Acharya et al., 1989; Parry et al., 1990) . Furthermore, studies indicate that synthetic peptide vaccines are capable of conferring broader protection than the conventional whole virus vaccine Doel et al., 1990 Doel et al., , 1992 and do not readily select antigenic variants , thus fulfilling two of the requirements for an ideal vaccine for field application. However, serological assays of anti-viral or anti-peptide titre correlate poorly with protection, in contrast to the well established relationship between serum neutralization tests and protection of virus vaccinated cattle. This difference may owe much to the different specificities, avidities and isotypes of antibodies induced by virus and peptide vaccines.
One approach to the question of the specificity of antibodies induced by peptides is to fully characterize anti-peptide MAbs. Studies by Barnett et al. (1993) using a panel of MAbs raised against a peptide encompassing residues 156-170 of VP2 of human rhinovirus type 2 resulted in the classification of four main reaction groups. Group 1, antibodies which recognized and neutralized native virus; group 2, antibodies which bound to intact 0001-3605 © 1996 SGM virus particles, but failed to neutralize infectivity; group 3, antibodies which recognized virus only after capsid distortions; and group 4 antibodies, which were peptide specific. Surprisingly, despite having these different biological activities many of the MAbs recognized the same minimum binding sequence (Barnett et al., 1995) .
In the present work, we have adopted a similar approach with FMDV peptides and have raised MAbs against a synthetic peptide equivalent to the 141-158 and 200-213 sequence of FMDV strain A24 Cruzeiro.
Methods
Peptides. All the pcptides used in this study were synthesized by conventional solid-phase methodology (Merrifield, 1963) . Peptide A40, used for the production of MAb C1.1, has been described previously (Doel et al., 1990) and was based on the published sequence of the VP1 protein of strain A24 Cruzeiro but with additional amino acids. This peptide has the general sequence Cys-Cys-(VP 1 200-213)-Pro-Pro-Ser-(VP1 141-158)-Pro-Cys-Gly, encompassing two regions previously shown to elicit virus neutralizing antibody (Strohmaier et al., 1982; Bittle et al., 1982) . For assay purposes various peptides corresponding to partial and complete epitopes were also produced including a set of overlapping peptides synthesized as 12 amino acid blocks. These were 'frame shifted' by one residue at a time to span the complete sequence of the immunizing peptide A40. In addition, twelve peptides representing the VP1 145-158 sequences of at least 17 known FMDV A subtypes (Weddell et al., 1985; Beck & Strohmaier, 1987) were synthesized.
Monoclonal antibody. CI.1 was produced from a BALB/c mouse previously immunized by the intraperitoneal inoculation of 10 lag of oil-adjuvanted peptide, followed 28 days later by a second intraperitoneal dose of 20 lag of oil-adjuvanted peptide and a final inoculation of 100 lag of unadjuvanted peptide at day 50. All immunizations of peptide were without the use of any carrier molecule. Hybridoma cell lines were obtained by fusing spleen cells from this mouse, recovered 3 days after the third inoculation, with NS0 mouse myeloma cells using PEG 3350 (Sigma) and a modification of the technique described by Butcher et al. (1991) . The hybridomas were grown in DMEM containing 10 % fetal calf serum, 2 mM-L-glutamine, HAT supplement and antibiotics, and cloned in methyleellulose. Single colonies were screened both by indirect ELISA against the immunizing peptide and sandwich ELISA against virus, and any individual colonies showing positive reactivity were subsequently grown to large volume. Despite the identification of a reasonable number of hybridomas only CI.1 showed any ability to neutralize infectivity. Consequently, pools of supernatant medium from this monoclone were concentrated approximately 20-fold by ultrafiltration using a Minitan S tangential flow system (Millipore) for subsequent characterization studies and quantitatively assayed by radial immunodiffusion (Serotec) against known antibody standards.
Isotyping. Antibody class and subclass were determined by the Ouchterlony double immunodiffusion technique using a commercially available kit (The Binding Site Ltd, Birmingham, UK).
Viruses. The ~ollowing strains of FMDV were prepared from infected baby hamster kidney (BHK) 21 cell monolayers: A24 Cruzeiro Brazil/55, A2~ Cundinamarca Colombia/76, A Argentina/79, A Venceslau Brazil/76, A Portugal 1983 and A22 Iraq 24/64. The virus stocks used for the microneutralization tests were stored as clarified tissue culture harvest material at -20 °C in 50% glycerol. For other immunoassays, virus was purified by the method of Brown & Cartwright (1963) ELISA techniques'. Anti-peptide activity was determined by indirect ELISA. Peptides, diluted to 2 lag/ml in carbonate/bicarbonate buffer (15 mM-Na2CO3, 35 mM-NaHCO3, pH 9.6), and applied at 100 lal/well, were used to coat microplates (Nunc Immunoplates II), air-dried at 37 °C and methanol-fixed. This was followed by successive additions of test sample and peroxidase-conjugated anti-mouse antibody (Dakopatts), using PBS which contained 2 % skimmed milk powder as the diluent. The plates were thoroughly washed in PBS containing 0.05 % (v/v) Tween 20 prior to each addition and incubated for at least 1 h at 37 °C afterwards. The tests were developed using o-phenylene diamine/peroxide substrate in citrate buffer, stopped with 12.5 % (v/v) sulphuric acid and absorbances read at 492 nm on a Titertek Multiskan spectrophotometer. Anti-virus activity was assessed by indirect, indirect sandwich or competition ELISA. The indirect test was essentially as described above, hut without air-drying and methanol fixing, using virus at a similar concentration. For the sandwich ELISA, rabbit anti-FMDV IgG (1/5000) was bound to microplates and used to capture purified virus particles from a suspension of 2 lag/ml. Subsequent stages of the test were the same as those of the indirect ELISA. The competition test was a modification of the indirect sandwich technique. At the stage of antibody addition a constant predetermined dilution of the MAb preparation was reacted with serial dilutions of a competitor antigen before adding it to the virus coated test plates.
Epitope mapping. The minimal binding site of MAb CI.1 was determined by the indirect peptide ELISA technique described earlier using the set of overlapping peptides that encompassed the full peptide A40 sequence.
Neutralization assay. This was performed using a two-dimensional microneutralization technique similar to that described by Booth et al. (1978) . Briefly, doubling dilutions of antibody were reacted with 0.5 loga0 dilutions of virus for 1 h; BHK-21 cells were then added as indicators of residual infectivity and the microplates were incubated at 37 °C for 3 days prior to fixing and staining. CI.1 antibody titres were calculated from regression data as the log10 reciprocal antibody dilution required for 50 % neutralization of 10 tissue culture infective units of virus (logl0SN~0/10 TCID~0 ). For comparative purposes the neutralizing ability of bovine A24 Cruzeiro polyclonal antiserum was also examined against the same panel of viruses tested with MAb C 1.1, but with the logl0SNs0 value calculated at a dose level of 100 TCID50. The antigenic relationship of viruses based on their neutralization by MAb or serum is given by the ratio : r = neutralization titre against the heterologous virus/neutralization titre against the homologous virus. The significance of differences in the values of r obtained with the polyclonal antiserum was evaluated according to the criteria of Rweyemamu & Hingley (1984) .
Mouse protection test. This was carried out as described by Mulcahy et al. (1991) . Four-to eight-day-old suckling mice (CD1) were inoculated subcutaneously with a specific range of MAb CI.1 concentrations. One hour later they were inoculated intraperitoneally with 0-03 ml of a dilution of challenge virus. Five, tenfold serial dilutions of virus (10 -~, 10 3, 10 4, 10-5 and 10 6), were used for each test and the IDs0 of the virus was calculated by the method of Karber (1931) . The IDs0 value for the virus in the absence of immune antibody was usually 6.0 log10. Results were expressed as T= loga0V-log~0S where T = protective antibody titre, V = IDs0 of the virus in control mice and S = IDso of the virus in the presence of test MAb. A reduction in infectivity of 3 x log10 compared to the control titre (T >~ 3) was considered to represent complete protection. For comparative purposes only T values at the MAb concentration of 0.832 gg per mouse are shown for each of the virus strains examined.
Results
An anti-peptide MAb was derived from a BALB/c mouse multiply immunized with a synthetic peptide equivalent to two virus coded VP1 capsid sequences of FMDV strain A24 Cruzeiro. Preliminary characterization of this antibody, designated C 1.1, showed that it was of the IgG1 subclass and that it recognized homologous peptide, denatured or intact virus particles in ELISA and also neutralized infectivity in an in vitro assay. In addition, the MAb was capable of recognizing isolated VP1 in a Western blot (results not shown). That the MAb was qualitatively effective was demonstrated with a passive immunity test in suckling mice. Using a range of antibody concentrations, CI.1 conferred complete protection at a dose level as low as 0-0832 gg of purified IgG per mouse (Fig. 1) .
A series of 12 amino acid blocks, frame-shifted by one residue at a time to span the complete A40 peptide sequence, was used to determine the minimum binding footprint of C I.1 as deduced from the shared linear sequences of those peptides showing reactivity in an indirect ELISA. It was demonstrated that the minimum binding sequence of this antibody was contained within the 141-158 region of the A40 peptide and corresponded to residues 149-154 (GSLAAR) of VP1 (Fig. 2) . Examination of other A serotype virus sequences, representative of the particular antigenic variability of this serotype, revealed that this binding region was fairly conserved, often with only a single amino acid change occurring. Thus, studies involving the use of these other A strains might reveal some cross-reactive properties of this MAb and offer a means of identifying critical residues without the need to produce escape mutants. Initially, 12 synthetic peptides (TBI-12), representing VP1 residues 147-158 of at least 17 known A serotype viruses, were examined by a liquid-phase competition ELISA. Apart from the homologous sequence depicted by peptide TB 1 only two other peptides, TB2 and TB4, showed strong reactivity with CI.1 (Table 1) . However, P. V. Barnett and others a detectable level of reactivity was also observed against peptide TB3, suggesting that such reactivity is of low affinity. The results obtained with peptides TB2 and TB4 indicated that C1.1 should have the potential to react with five A subtypes other than A24 Cruzeiro. Three of these, A27 Cundinamarca Colombia/76, A Argentina/79 and A Venceslau Brazil/76, represented by peptide TB2, shared the same minimum binding footprint as that of homologous A24 Cruzeiro virus. The other two viruses, A Spain Madrid 3/83 and A Portugal 1983, exemplified by TB4, had an amino acid substitution, A 152 ~T, within the minimum footprint. In contrast, the inability of CI.1 to recognize the other peptides from this panel suggested that some residues within the minimum binding sequence were critical for binding including the serine, leucine and alanine residues at positions 150, 151 and 153 respectively. To establish whether MAb C 1.1 was able to recognize those A viruses equivalent to peptides TB1, TB2 and TB4, sucrose density gradient purified preparations of the viruses were assayed in indirect, indirect sandwich and competition ELISAs.
For all three of the different ELISA techniques employed the homologous A24 Cruzeiro virus gave equivalent or greater reactivity than any of the other subtypes tested (Fig. 3) . However, the profiles observed, in each different assay, were quite distinct. In the competition ELISA, for example, the sigmoid curve profiles produced by A Argentina/79, A~7 Cundinamarca Colombia/76 and A Venceslau Brazil/76 showed remarkable resemblance (Fig. 3c) , whereas A Portugal, containing the A TM ~ T substitution within the minimum binding sequence, showed a marked reduction in its reactivity to C1.1. The latter was also observed with the other ELISA methods. The similarity in profiles of A Argentina/79, A~7 Cundinamarca Colombia/76 and A Venceslau Brazil/76 in the competition ELISA was not observed with either the indirect (Fig. 3 a) or sandwich ELISA (Fig. 3 b) . While the homologous reaction was always dominant, the relative reactivities with the heterologous viruses differed among all the tests. For example, the relative reactivities of A Argentina/79 and A Venceslau Brazil/76; also, the relative reactivities of A24 Cruzeiro and A27 Cundinamarca Colombia/76. Having established that CI.1 recognized other A strain viruses, the extent to which this MAb reduced the infectivity of these strains was also examined using a two-dimensional microneutralization technique. All of the strains that were recognized in the liquid phase competition ELISA were neutralized by this MAb and the values obtained ranged from 1.14 to 1.76 loga0SNs0/10 TCIDs0 (Fig. 4a) . But surprisingly, in the light of the similar competition profiles of A Argentina/79, A27 Cundinamarca Colombia/76 and A Venceslau Brazil/76, C1.1 appeared to be less effective at neutralizing the latter strain. However, the crossreactivity of this MAb was no greater than that observed with A~4 Cruzeiro bovine polyclonal antiserum (Table 2) .
Finally, results from the mouse protection test using these same virus strains (Fig. 4 b) 
Discussion
A peptide based on two FMDV A24 Cruzeiro virus VP1 sequences, linked by a Pro-Pro-Ser spacer, was used to immunize BALB/c mice for MAb production. This pcptide (A40) induced a MAb, C 1.1, of the isotype IgG 1, The (r) values shown represent the neutralization titre against heterologous virus/neutralization titre against homologous virus.
* r significantly less than 1.0 (P = 0.05). ** r significantly less than 1.0 (P = 0.01).
which recognized the homologous peptide, bound both to native virus particles and to particles distorted after adsorption onto a solid phase (McCullough et al., 1985) and measurably neutralized virus infectivity. The protective ability of CI.1 was also examined using a passive immunity test (MPT), which has been shown to be a more accurate indicator of protection in the target species than conventional serum neutralization assays, particularly when examining the response following vaccination with synthetic peptides (Mulcahy et al., 1991) . C1.1 was shown to be capable of fully protecting suckling mice against homologous FMDV challenge at an antibody dose level of 0.0832 ~tg per mouse and against two heterologous strains, A Argentina/79 and A27 Cundinamarca Colombia/76, when the antibody concentration was increased tenfold. Similar studies using MAbs raised against a synthetic peptide that included residues 156-170 of protein VP2 of another picornavirus, human rhinovirus type 2 (HRV2), have also been made (Barnett et al., 1993) . In this work the panel of antibodies was classified into four main reactivity groups. Although all of the MAbs isolated recognized the homologous peptide, the first group had essentially the same characteristics as CI.1, that is they recognized and neutralized native virus. However, it is not clear if the characteristics of C1.1 are equivalent to that of reactivity group 1 because of its additional and important ability to protect mice passively. The lack of a similar passive protection test for HRV2 therefore leaves the question of whether C I.1 defines a further main reactivity group unresolved.
The protecting/neutralizing epitope to which this antibody was directed comprised residues 149-154 of VP1, namely GSLAAR. Previously, anti-virus MAbs also highlighted this region as being an important neutralizing epitope of A~ Iraq 24/64 (Bolwell et al., 1989) , with critical residues being identified at positions 149, 150, 153 and 154. Uncoupled synthetic peptides therefore appear to be capable of eliciting antibodies that precisely mimic those produced following immunization with the native virus. This epitope lies immediately adjacent on the C-terminal side of a highly conserved RGD sequence that is essential for the initial attachment of FMDV to susceptible cells Mason et al., 1994) . It was therefore possible that CI.1 could neutralize infectivity by steric hindrance, because of the close proximity of the epitope to the cell attachment site. However, preliminary analysis of the ability of CI.1 to inhibit virus attachment to BHK cells did not conclusively demonstrate this to be the major mechanism of neutralization as approximately 65 % of the virus was still able to bind to cells (results not shown). This is consistent with the observations that the RGD flanking sequences are not directly involved in the attachment process and that nonconservative substitutions just C-terminal of the RGD had no detectable effect on virus growth (Mason et al., 1994) . Interestingly, Fab fragments of CI.1 were unable to neutralize infectivity or protect suckling mice from challenge at levels twofold or greater than the highest uncleaved antibody concentrations tested, despite still recognizing virus (data not shown). This suggests that bivalent attachment to the virion may be an important component in the neutralization/protection mechanism of CI.1, although there is a case for both inhibition of cell attachment and bivalency playing a part in the inactivation of the virus. If the cross-linking resulting from bivalent attachment is not merely aggregating the virus (Brioen et al., 1983; Thomas et al., 1985) , it could be stabilizing the capsid shell and thus preventing virus uncoating and release of the viral RNA following internalization (Mosser et al., 1989; Wetz, 1993) . Further studies to investigate these particular parameters are planned.
It has been previously shown that antibodies raised to a peptide similar to A40, but containing two VP1 Cterminal regions of type O FMDV, neutralized a wider range of type O FMDV isolates than anti-virion serum . The structural and antigenic basis for this remains unclear, although similar cross-reactivity is also conferred by antibodies raised to peptides encompassing the 140-160 sequence alone . Comparison of the sequences comprising 149-154 of VPI of a number of A subtype viruses (Weddell et al., 1985; Beck & Strohmaier, 1987) revealed that this region was reasonably conserved within a region of hypervariability, and often included only a single amino acid change. Based on this and also the observation that a single mutational change within an epitope may also enhance binding and neutralization by an antibody (Ferguson et al., 1986; Barnett et al., 1995) it was decided to determine if C 1.1 could cross-react with other A type strains. Preliminary assessment using a panel of 12-mer peptides encompassing VP1 residues 147-158 representing at least 17 different A strains indicated that almost all of the naturally occurring mutations within the minimum binding sequence abrogated binding. Indeed, the only change that could be accommodated by CI.1 while retaining a reasonable level of reactivity was A1'~2~ T. Surprisingly, a detectable level of reactivity was also seen with the peptide representing the A32 Venezuela/70 that included a substitution S 15° ~ P, but this was not confirmed with the A22 Iraq 24/64 peptide which shared this same substitution. Consequently, the virus strains, identified with the panel of peptides, as being potentially cross-reactive with CI.1 generally shared the same minimum binding region as that of the homologous virus. Despite sharing the same epitope these viruses reacted very differently with CI.1, depending on the serological assay employed. The ability of C1.1 to be inhibited by these other strains in liquid phase ELISA showed that although none of the strains had a greater ability to inhibit than the homologous virus, three viruses, A Argentina/79, A27 Cundinamarca Colombia/76 and A Venceslau Brazil/76, had equivalent reaction profiles, suggesting a similar functional affinity of CI.1 for each of these strains. However, this was not the case with virus adsorbed directly onto a solid phase or captured with polyclonal antibodies. Previous studies have shown similar variations in reactivity depending on the ELISA system employed (McCullough et al., 1985) , and it was suggested that MAbs which bound preferentially to liquid phase antigen probably recognized epitopes whose accessibility is altered by binding to plastic or interaction with polyclonal (trapping) antibody. This would appear to be the case for our VP1 specific MAb CI.1. Nevertheless, the variation of reactivity observed among the different virus strains used under the differing conditions suggests that the overall architecture of the virion also plays a major role in dictating the extent to which the G-H loop of VP1 is exposed. Variation was also seen in the efficacy of CI.1 in neutralizing infectivity and protecting suckling mice against challenge with these A strains. Although measurable levels of neutralization were observed with all of the strains examined, the extent of this cross-neutralization was no greater than that normally observed in the polyclonal response following vaccination with inactivated A~ Cruzeiro virus. This supports the finding that neutralizing polyclonal antibodies raised against synthetic peptides corresponding to the VP1 140-160 sequence of A22 Iraq 24/64 also gave no greater crossneutralization than that observed with anti-viral polyclonal serum (Bolwell et al., 1989) . In contrast, synthetic peptides representing some strains of FMDV do elicit broader specificity as observed by neutralization and protection Doel et al., 1990 Doel et al., , 1992 when compared with conventional anti-viral responses. However, such cross-protection cannot be attributed to any single sequence as both the 141-160 and 200-213 VP1 regions have been implicated. MAb C1.1 neutralized A Portugal less effectively than the homologous strain, complimenting the reactivities observed by ELISA. Surprisingly, one of the heterologous viruses, A Venceslau Brazil/76, was not as efficiently neutralized as A27 Cundinamarca Colombia/76 and A Argentina/79 despite the identical minimum binding sites. This phenomenon was also observed with the protection data, suggesting that the similar functional affinities of A27 Cundinamarca Colombia/76, A Argentina/79 and A Venceslau Brazil/76 with C1.1, seen in the liquid phase ELISA, did not correlate with similar levels of neutralization or protection. Recently, it has been shown that MAbs to a peptide of HRV2 which recognize the same minimum sequence and with similar functional affinities can have different specificities (Barnett et al., 1993 (Barnett et al., , 1995 . In this study, it would appear that functional disparity of an anti-peptide antibody with other A strains can also occur, even though these different viruses contain the same minimum binding sequence and show similar affinities. This would suggest that the endowment of the functional properties of an antibody is not limited entirely to sequence recognition. There are many examples of amino acid substitutions occurring outside an epitope which sterically affect antibody recognition (Ibrahimi et al., 1979; A1 Moudallal et al., 1982; Cooper et al., 1987; Parry et al., 1990; Barnett et al., 1995) . Moreover, recent crystallographic evidence has also shown that flanking amino acids, outside the minimum binding epitope as defined by a set of overlapping peptides (Hastings et al., 1990) , are nevertheless important in the interactions between peptide and antibody (Tormo et al., 1994) . Sequential differences elsewhere on the capsid or at close proximity to the defined epitope are therefore likely to play a role in determining the overall efficacy of C 1.1.
This study has identified an antibody that is representative of the desirable immune response following vaccination with synthetic peptide and has allowed the determination of an amino acid sequence which is critical for both binding and the induction of neutralizing/ protective antibodies. Previous studies on the polyclonal response to synthetic FMDV peptides have revealed that the high antibody titres capable of neutralizing FMDV in vitro are less effective in passively protecting mice against challenge (Mulcahy et al., 1991) . The reason why the polyclonal anti-peptide serum did not protect mice remains unclear, although factors such as interference of protective antibodies by non-protective antibodies or a total population of partially effective antibodies, cannot be ruled out. In terms of protection, CI.1 represents a highly effective anti-peptide antibody which either is not normally induced or is present at very low levels in typical polyclonal anti-peptide responses. In order to determine the structural basis of effective neutralization/protection, our investigations will need to be extended with crystallization studies. Short but important peptide sequences such as that defined by C 1.1 offer an invaluable tool in evaluating novel systems of peptide presentation. It remains to be seen if constructs incorporating this short protective epitope alone can induce the appropriate humoral response. Nevertheless, induction of high titres of an antibody like CI.1 in a target species could have a dramatic impact on the prospects for synthetic FMDV vaccines.
